A better grasp onto the pathways mediating the action of PD-1 and CTLA-4 blockade on the tumor is important to enhance our ability to monitor for their effects in patients in real time, thereby addressing the uncertainty in treatment outcome following their introduction. This evidence concerns the gene CTLA4 and neoplasm.